Mounjaro for PCOS — what the evidence shows and what to expect

What PCOS actually is, briefly

Polycystic ovary syndrome (PCOS) is a hormonal and metabolic condition affecting around 1 in 10 women of reproductive age. It's diagnosed using the Rotterdam criteria — you need at least two of: irregular or absent ovulation, clinical or biochemical signs of androgen excess (acne, hirsutism, scalp hair thinning, raised testosterone), and polycystic ovarian morphology on ultrasound. The name is a bit misleading: not everyone with PCOS has cysts on the ovaries, and not everyone with cysts has PCOS.

The metabolic side is what often dominates the lived experience. Insulin resistance is present in roughly 70–80% of women with PCOS, regardless of body weight, but it's amplified by excess weight and often drives the cascade: insulin resistance → higher insulin levels → increased ovarian androgen production → acne, hirsutism, anovulation, irregular cycles, weight gain, mood changes, increased cardiometabolic risk. Standard weight loss advice rarely works as expected because the underlying physiology fights back.

Why GLP-1/GIP medication matters for PCOS

Tirzepatide (Mounjaro) is a once-weekly injectable peptide that activates both GLP-1 and GIP receptors, the gut hormone pathways the body uses to regulate appetite, satiety, gastric emptying, and insulin response. For a full explanation of how the molecule works, see our Mounjaro explainer. For how it compares with semaglutide (Wegovy), see Mounjaro vs Wegovy.

For PCOS specifically, the relevant effects are:

• Direct weight reduction. Sustained 15–20%+ average weight loss is meaningful in PCOS, where even modest weight loss (5–10%) can restore ovulation in a proportion of women and improve metabolic markers.
• Improved insulin sensitivity. Both GLP-1 and GIP pathways influence insulin response and glucose regulation. Combined with weight loss, the result is often a clear reduction in fasting insulin and HbA1c.
• Reduced androgen-driven cascade. As insulin levels fall, ovarian androgen production tends to fall too, with knock-on improvements in acne, hirsutism, and sometimes scalp hair, over months.
• Reduced food noise and binge patterns. Many women with PCOS describe a constant, exhausting relationship with food (linked to insulin resistance and reward signalling). Tirzepatide's appetite-modulating effect is often described as the noise being turned down for the first time in years.

What the evidence actually shows

The trial evidence base for GLP-1/GIP medication specifically in PCOS is still developing, but the picture is consistent. Trials of semaglutide and liraglutide in PCOS populations have shown:

• Significant weight reduction, consistent with effects in non-PCOS populations.
• Improvements in menstrual cyclicity and markers of ovulation in a substantial proportion of participants.
• Reductions in free testosterone and improvements in some androgenic symptoms over 6–12 months.
• Improvements in insulin resistance markers (HOMA-IR) and lipid profile.

Tirzepatide-specific PCOS evidence is more recent and smaller in scale, but mechanistically the dual GIP/GLP-1 activity would be expected to produce equal or larger benefits given the bigger weight loss seen in head-to-head SURMOUNT-5 data against semaglutide. Real-world clinical experience in pharmacist-led programmes lines up with this.

The Monash 2023 international evidence-based PCOS guideline supports the use of GLP-1 receptor agonists as part of weight management in PCOS where lifestyle approaches alone have been insufficient and BMI criteria are met. Tirzepatide is newer than the guideline; it sits within the same therapeutic class for these purposes.

The licence vs the prescribing reality

Mounjaro is not licensed for PCOS in the UK. It's licensed for chronic weight management (BMI ≥30, or 27–30 with a weight-related comorbidity) and for type 2 diabetes. In practice, this means women with PCOS access it via the weight management licence — and PCOS itself contributes to several qualifying comorbidities (type 2 diabetes, prediabetes, hypertension, dyslipidaemia).

For NHS access via NICE TA1026, criteria are tighter: BMI ≥35 (≥32.5 in some ethnic groups, including South Asian, Chinese, Black African, and African-Caribbean) plus at least one comorbidity, through specialist weight management services. PCOS does not directly open the NHS pathway; the BMI and comorbidity criteria do. For more on the routes, see our guide to NHS Tier 3 vs private weight loss.

What women with PCOS often notice first

The patterns we see most often, in rough order:

• Weeks 1–2. Appetite quietens. Snacking becomes effortful rather than automatic. Some mild nausea, especially after fattier meals — the standard portion-control advice applies.
• Weeks 3–6. Weight starts moving consistently. Energy often improves. Food cravings (especially carbohydrate cravings that are commonly amplified by PCOS-driven insulin swings) tend to fade.
• Months 2–3. Cycles can start to become more regular. This is the moment the contraception conversation becomes urgent (see below).
• Months 3–6. Continued weight loss; insulin markers improve; some women see early signs of acne improvement. Energy levels often stabilise after the early adjustment period.
• Months 6–12. Slower but continued weight reduction. Hirsutism and androgen-related skin changes can start to slowly soften. Most women on a structured programme are settling into a maintenance dose by now.

The fertility conversation — the most important one

Two things happen at once on Mounjaro that matter for fertility:

1. Anovulation often reverses. If irregular cycles in PCOS are driven by insulin resistance and weight, addressing both can restore ovulation — sometimes faster than expected. Women who have had irregular or absent cycles for years can become reliably fertile within 3–6 months of starting treatment.
2. Tirzepatide must not be used in pregnancy. It's not licensed for use in pregnancy and animal data raised concerns about fetal development. The MHRA advice is to stop at least 4 weeks before planned conception, with some clinicians preferring 6–8 weeks.

The combination is the problem: you become more fertile while taking a medication that absolutely cannot continue into pregnancy. This is why the contraception conversation is unavoidable. If you don't want to be pregnant, you need effective contraception throughout treatment and you need to know about the dose-step risk windows for oral contraceptives — see our Mounjaro and contraception guide for the detail.

If you are actively trying to conceive, Mounjaro isn't the right medication. A planned weight management approach in advance of pregnancy — working with your GP and, where appropriate, an NHS specialist or fertility service — is the safer route. The window for pre-pregnancy weight loss is its own clinical conversation.

Side effects in the PCOS demographic

The side effect profile of Mounjaro is the same as in non-PCOS patients (see our month-by-month side effects guide), but a few PCOS-specific notes:

• GI side effects (nausea, mild constipation). Standard — settles within 1–2 weeks per dose step. Smaller portions, slower eating, hydration.
• Mood and energy. PCOS is associated with higher baseline rates of anxiety and depression. Most women see mood and energy improve as insulin resistance and weight loss improve, but a small number find low mood worsens on GLP-1 medication. Talk to your clinician if this is your experience.
• Hair shedding (telogen effluvium). Any rapid weight loss can trigger hair shedding 2–4 months in, which is usually temporary and recovers over 6–12 months. Don't confuse this with PCOS-driven androgenetic thinning, which is a different mechanism and pattern. Adequate protein intake during weight loss helps.
• Restored periods can feel disruptive. Women who haven't had a regular period in years may find their return unexpectedly intense, especially in the first 2–3 cycles. This is the body's normal pattern returning, not a side effect of the medication directly.

Co-management with metformin

Many women with PCOS are already on metformin for insulin resistance. Continuing it alongside tirzepatide is reasonable and the two medications work on different pathways: metformin reduces hepatic glucose output and improves insulin sensitivity; tirzepatide reduces appetite, slows gastric emptying, and amplifies satiety signalling.

Practical points:

• You don't need to stop metformin to start Mounjaro.
• If you've struggled with GI side effects on metformin, the addition of tirzepatide can briefly amplify them — worth flagging to your prescriber.
• Over months, some women find appetite suppression and weight loss are doing the job sufficiently that metformin can be tapered or stopped. That's a clinical decision based on response, not something to do unilaterally.
• Blood glucose / HbA1c monitoring continues either way; the combined effect can be substantial.

Hair changes — PCOS vs Mounjaro shedding

Two different processes can affect hair in women on Mounjaro for PCOS:

1. Telogen effluvium. Temporary diffuse hair shedding 2–4 months after starting any rapid weight loss intervention. Usually peaks around month 3–4 and recovers over 6–12 months once weight loss slows and nutritional intake stabilises. Adequate protein intake (often underestimated during weight loss) and a balanced micronutrient profile help.
2. PCOS-related changes. Hirsutism (excess facial/body hair) and androgenetic scalp thinning are both androgen-driven. Reducing insulin resistance and weight tends to reduce androgen excess over months — these changes are slower to appear but more durable.

If hair shedding is concerning, talk to your clinician. A baseline check of ferritin, B12, vitamin D, and thyroid function is worth doing if not already on record.

When PCOS isn't the right primary diagnosis

If you've been told you have PCOS but you've never had a full diagnostic workup, the conversation deserves a pause. Some conditions that can present similarly include thyroid dysfunction, hyperprolactinaemia, non-classical congenital adrenal hyperplasia, Cushing's syndrome, and androgen-secreting tumours. These need different treatment.

If your PCOS diagnosis is solid (Rotterdam criteria met, other conditions excluded), Mounjaro is one tool in a broader management plan that also includes ongoing care from your GP, sometimes a gynaecologist or endocrinologist, and lifestyle support.

The structured programme angle

Following MHRA action on prescribing standards, every UK Mounjaro prescription must sit within a structured weight management programme. For PCOS this matters more than usual, because the medication is one component of a wider picture: insulin resistance management, cardiometabolic risk, fertility planning, mental health, and ongoing gynaecological care. A responsible programme includes clinical consultation, dietary and behavioural support, monitoring, side effect management, and a clear plan for maintenance and discontinuation.

For women planning future pregnancy, the structured programme also covers the off-ramp — when and how to stop, what to expect in the washout period, and how to maintain the gains made during treatment.

The next step

If you have PCOS and are considering Mounjaro, the most useful single step is a 30-minute weight management consultation. Bring details of your PCOS diagnosis, current cycles, any related conditions (insulin resistance, type 2 diabetes, hypertension, dyslipidaemia), any fertility plans (current or future), your current medications (including metformin and contraception), and a recent weight and BMI if available. The consultation will confirm eligibility, set expectations, and start a structured programme that fits how you live.